PPAR-α and insulin sensitivity

被引:84
作者
Haluzik, M. M.
Haluzik, M. [1 ]
机构
[1] Charles Univ Prague, Dept Med 3, Fac Med 1, Nemocnice 1, Prague 12808 2, Czech Republic
[2] Univ Hosp Prague, Prague, Czech Republic
[3] Univ Ostrava, Dept Chem, Fac Sci, Ostrava, Czech Republic
关键词
peroxisome proliferator-activated receptor-alpha; insulin sensitivity; obesity; adipose tissue;
D O I
10.33549/physiolres.930744
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Peroxisome proliferator-activated receptors (PPAR) belong to the nuclear receptor superfamily of ligand-activated transcription factors. PPAR-alpha, first of its three subtypes (alpha, beta, gamma) has traditionally been considered an important regulator of lipid metabolism while its role in the regulation of insulin sensitivity has not been recognized until recently. Here we summarize the experimental and clinical studies focusing on the role of PPAR-alpha in the regulation of insulin sensitivity. In most of the experimental studies the activation of PPAR-alpha in rodents leads to improvement of insulin sensitivity by multiple mechanisms including improvement of insulin signaling due to a decrease of ectopic lipids in non-adipose tissues and decrease of circulating fatty acids and triglycerides. In contrast, the effect of PPAR-alpha agonist in humans is much less pronounced probably due to a lower expression of PPAR-alpha relative to rodents and possibly other mechanisms. Further clinical studies using more potent PPAR-alpha agonists on a larger population need to be performed to evaluate the possible role of PPAR-alpha in the regulation of insulin sensitivity in humans.
引用
收藏
页码:115 / 122
页数:8
相关论文
共 53 条
[1]   Hepatocellular proliferation in response to a peroxisome proliferator does not require TNFα signaling [J].
Anderson, SP ;
Dunn, CS ;
Cattley, RC ;
Corton, JC .
CARCINOGENESIS, 2001, 22 (11) :1843-1851
[2]   Regulation of fasted blood glucose by resistin [J].
Banerjee, RR ;
Rangwala, SM ;
Shapiro, JS ;
Rich, AS ;
Rhoades, B ;
Qi, Y ;
Wang, J ;
Rajala, MW ;
Pocai, A ;
Scherer, PE ;
Steppan, CM ;
Ahima, RS ;
Obici, S ;
Rossetti, L ;
Lazar, MA .
SCIENCE, 2004, 303 (5661) :1195-1198
[3]   Free fatty acids in obesity and type 2 diabetes:: defining their role in the development of insulin resistance and β-cell dysfunction [J].
Boden, G ;
Shulman, GI .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2002, 32 :14-23
[4]   WY14,643, a peroxisome proliferator-activated receptor α (PPARα) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice [J].
Chou, CJ ;
Haluzik, M ;
Gregory, C ;
Dietz, KR ;
Vinson, C ;
Gavrilova, O ;
Reitman, ML .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (27) :24484-24489
[5]   Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes [J].
Cline, GW ;
Petersen, KF ;
Krssak, M ;
Shen, J ;
Hundal, RS ;
Trajanoski, Z ;
Inzucchi, S ;
Dresner, A ;
Rothman, DL ;
Shulman, GI .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :240-246
[6]   Secondary preventive potential of lipid-lowering drugs - The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) [J].
deFaire, U ;
Ericsson, CG ;
Grip, L ;
Nilsson, J ;
Svane, B ;
Hamsten, A .
EUROPEAN HEART JOURNAL, 1996, 17 :37-42
[7]   Functional inactivation, of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes [J].
Fernández, AM ;
Kim, JK ;
Yakar, S ;
Dupont, J ;
Hernandez-Sanchez, C ;
Castle, AL ;
Filmore, J ;
Shulman, GI ;
Le Roith, D .
GENES & DEVELOPMENT, 2001, 15 (15) :1926-1934
[8]   EFFECTS OF SHORT-TERM CLOFIBRATE ADMINISTRATION ON GLUCOSE-TOLERANCE AND INSULIN-SECRETION IN PATIENTS WITH CHEMICAL DIABETES OR HYPERTRIGLYCERIDEMIA [J].
FERRARI, C ;
FREZZATI, S ;
ROMUSSI, M ;
BERTAZZONI, A ;
TESTORI, GP ;
ANTONINI, S ;
PARACCHI, A .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1977, 26 (02) :129-139
[9]   PPARs, metabolic disease and atherosclerosis [J].
Fruchart, JC ;
Staels, B ;
Duriez, P .
PHARMACOLOGICAL RESEARCH, 2001, 44 (05) :345-352
[10]   Expression of resistin in the adipose tissue is modulatedby various factors including peroxisome proliferator-activated receptor α [J].
Fukui, Y ;
Motojima, K .
DIABETES OBESITY & METABOLISM, 2002, 4 (05) :342-345